Written Blog — The Clinical Trials Guru

Contract Research Organizations show good 4th quarter results

Dan SferaMarch 14, 2022Comment

Biotech company aims to transform medicine via cellular rejuvenation programming

Dan SferaFebruary 28, 2022Comment

AstraZeneca partners with Scorpion for hard-to-get cancer targets

Dan SferaFebruary 28, 2022Comment

Candid Discussion on COVID Treatments, Vaccines and Research

Dan SferaFebruary 28, 2022Comment

Targeting with Transfer RNA: Startup gets $24 million in funding

Dan SferaFebruary 28, 2022Comment

Intestinal studies show immunosuppressive effects of COVID-19

Dan SferaFebruary 28, 2022Comment

Trends for 2022: Brief provides focus for pharma

Dan SferaFebruary 28, 2022Comment

Biotech Breakthroughs: Some advances of 2021 missed the headlines they deserve

Dan SferaJanuary 9, 2022Comment

Five for the First Quarter: What will FDA approve?

Dan SferaJanuary 9, 2022Comment

Best of Biopharma: Here are the top stories of 2021

Dan SferaJanuary 9, 2022Comment

Volatile or not, Ardelyx is getting attention

Dan SferaJanuary 9, 2022Comment

First Wave announces RESERVOIR recommendation

Dan SferaDecember 29, 2021Comment

Analysts emphasize upside of Qualigen

Dan SferaDecember 29, 2021Comment

Lawrence Tabak becomes incoming acting NIH director

Dan SferaDecember 29, 2021Comment

Analysts anticipate future growth of biopharma company

Dan SferaDecember 29, 2021Comment

FDA gives AstraZeneca-Amgen drug broad approval

Dan SferaDecember 29, 2021Comment

Former FDA auditor offers honest appraisal of vax development process

Dan SferaDecember 29, 2021Comment

New normal keeps pharma remote audits

Dan SferaDecember 29, 2021Comment